CS Paper Radar

TrialJev: Open-Weight Single Pass Eligibility Scoring for Patient Trial Screening

Omar Ibrahim, Grant Hamblin, Benjamin Haibe-Kains

cs.LG ·submitted 2026-11-06 19:11 UTC · v1
code/data

Abstract

Clinical trial screening requires assessing large numbers of patient-trial pairs to prioritize candidates for detailed eligibility review, often under restrictions on sharing patient records. We introduce TrialJev, an open-weight eligibility scorer that uses LoRA-adapted Qwen models and a pointer head to score natural-language answer options in a single forward pass, without autoregressive decoding. Trained on TREC Clinical Trials 2021 and evaluated on 6,975 eligible-or-excluded pairs from 50 unseen TREC 2022 synthetic patients, TrialJev achieves 80.97% (Qwen3.5-27B) and 81.84% (Qwen3.8-27B) accuracy, compared with 79.87% and 79.93% for LLMs fine-tuned on the same data to generate verdicts. In matched batch-1 measurements, verdict generation takes 2.45-2.70 times as long as the one-pass inference of TrialJev at 9B-27B. Under a common development-fitted decision correction, the two 27B TrialJev models reach 80.99% and 81.88% accuracy, compared with 81.28% for the proprietary hosted Jev API; paired confidence intervals include zero. TrialJev runs locally on a single GPU, requiring approximately 178 ms per pair at 27B, without transmitting patient text to an external model API. An A/B-logit ablation shows that avoiding decoding, rather than the pointer head alone, accounts for the measured efficiency advantage. TrialJev is intended for first-pass prioritization of candidate trials, complementing rather than replacing explanatory models and clinical review. Evaluation is limited to synthetic patients and implementation-specific timing, and clinical use has not been validated. Adapters, pointer heads, and model cards are released on Hugging Face.

Comment
38 pages. Code: https://github.com/oibrahi1/TrialJev. Models: https://huggingface.co/omareng/TrialJev

Closest papers

Nearest neighbours by meaning across the whole index.

Can JEV Support Clinical Trial Criteria Assessment?

cs.LG cs.AIcs.CL ·2026-10-26 ·Mengxian He, Ziyue Gao, Chun Li, Shunyi Zhang, Hao Wei +2 more
hot direction similarity 0.72
Abstract

Clinical trial prescreening requires distinguishing unmet conditions from insufficient evidence in patient records. Given patient records, criterion questions, and predefined answer options, we retrospectively compared JEV, a non-generative decision model returning native option probabilities, with schema-constrained Qwen Flash across 2,048 test patient-condition pairs from TrialGPT and question-answer datasets derived from MIMIC-III and MIMIC-IV, all evaluated under strict Zero Data Retention (ZDR) policies to ensure clinical data privacy. Both models assessed conditions individually or in batches sharing the same patient context, with performance measured against reference labels. In batch mode, JEV and Qwen achieved similar macro-F1 scores on TrialGPT (0.652 vs. 0.660) and MIMIC-IV (0.807 vs. 0.814), whereas JEV substantially outperformed Qwen on MIMIC-III (0.768 vs. 0.534; $Δ$ = +0.234, 95% CI: 0.187-0.281). This advantage largely reflected higher recall for conditions labeled as having insufficient information (56.3% vs. 9.9%). Across all three datasets, JEV also had lower observed median job latency (1.18-1.40 vs. 2.80-8.90 s) and 53%-74% lower estimated cost per condition. These findings position JEV as an initial assessment component that provides criterion-level judgments and flags potential information gaps for review. JEV's observed errors in interpreting clinical evidence underscore the need to verify its outputs against patient records before they inform eligibility decisions.

0.29

RECITE: Revising Eligibility Criteria Incorporating Textual Evidence

cs.AI ·2026-10-30 ·Russell Ro, Reza Abbasi-Asl
top venuebenchmark similarity 0.71
Abstract · 18 pages, 4 figures, 4 tables. Extended version of a paper in KDD 2026 (32nd ACM SIGKDD Conference on Knowledge Discovery and Data Mining). …

Overly restrictive eligibility criteria contribute to widespread enrollment failure in clinical trials, yet published recommendations for how specific criteria should be broadened remain disconnected from trial design at scale. We introduce RECITE (Revising Eligibility Criteria Incorporating Textual Evidence), a framework for automated discovery, extraction, and implementation of evidence-based eligibility criteria revisions. RECITE uses protocol amendment documents from ClinicalTrials.gov to construct a dataset of 11,913 curated instances across 5,735 trials, each pairing original criteria with documentary evidence and target revisions. We benchmark fifteen LLM configurations under truncated-to-context-window and retrieval-augmented generation conditions, on a 3,116-instance sample under an LLM-as-judge protocol validated against ten domain experts (judge vs. human quadratic-weighted Cohen's $κ_{qw} = 0.694 \pm 0.096$). The best open-weight model, Gemma 2 9B, achieves $κ_{qw}$-aligned ordinal score $3.0 \pm 0.9$ on a 0--4 scale (normalized 0.742) and the best closed-weight model, GPT-4o, reaches $3.0 \pm 0.8$ (normalized 0.745). Using an agentic literature discovery system, we then identified 44 paper--trial matches across five publications providing trial-design and EC-modification evidence. Our findings suggest that existing clinical knowledge can be operationalized into actionable trial design recommendations.

0.55

Advancing Clinical Trial Outcome Prediction with Domain-Specific Large Language Models

cs.AI ·2026-10-30 ·Burak Bakkar, Hana Moalla, Mohamed Salem Jedidi, Haifa Ben Messaoud, Nicolas Lopez Carranza
benchmark similarity 0.70
Abstract

Clinical trial failures are a major barrier to efficient drug development, incurring substantial costs and delaying patient access to effective therapies. Structured approaches such as the Hierarchical Interaction Network (HINT) predict trial outcomes by explicitly modelling interactions between drugs, diseases and protocols, but make limited use of the free text in trial registrations. We evaluate two domain-specific language models, BioBERT (108M parameters) and BioMistral (7B parameters), for phase-level outcome prediction on the TOP benchmark (12,477 trials), representing each trial as text built from ten ClinicalTrials.gov fields. We compare fine-tuning (full fine-tuning for BioBERT, low-rank adaptation for BioMistral) with probing, in which the pretrained model is frozen and only a lightweight classifier is trained on its embeddings. On the held-out test set of each phase, all four language-model variants achieved higher ROC-AUC (0.613--0.772) and PR-AUC (0.649--0.901) than the published HINT results, corresponding to relative PR-AUC gains of 10--20\%. F1 differences were small and mixed, and no model, including HINT, clearly exceeded the F1 of a trivial classifier that predicts success for every trial. Under the configurations tested, probing performed comparably to fine-tuning: fine-tuned models scored highest on ROC-AUC and PR-AUC in Phases I and II, and frozen BioMistral embeddings in Phase III (ROC-AUC 0.772; PR-AUC 0.901), although most differences between variants were below 0.03 and were not tested for significance. These results suggest that pretrained biomedical representations already encode signal relevant to trial outcome, and that probing is a computationally cheaper alternative to fine-tuning for this task.

0.22

MedJev: Evaluating Zero-Shot System-One Decision Making in Medicine

cs.CL cs.AIcs.LG ·2026-10-26 ·Simon A. Lee, Jiahang Sha, Moonseong Jeong, Yunbei Pan, Jeffrey N. Chiang
similarity 0.70
Abstract

System One decision models such as Jev answer structured questions in a single forward pass without generating text, offering fast and computationally efficient clinical decision support. We evaluate MedJev, an open System One model that runs locally on a laptop, across ten medical benchmarks spanning medical knowledge, diagnosis, and patient level prediction using MIMIC IV and MIMIC IV ED. We compare MedJev against zero shot LLM baselines, published GPT results, and supervised models. MedJev achieves accuracies of 72.5 percent on MedQA, 75.4 percent on USMLE, and 80.1 percent on NEJM, approaching published GPT 4 performance while maintaining well calibrated confidence estimates (ECE 0.028 to 0.063). On patient level tasks, MedJev achieves an AUROC of 0.926 for In Hospital Mortality, exceeding XGBoost (0.902), but underperforms supervised models on operational outcomes such as ED Triage Admission (0.745 vs. 0.809). Patient level predictions also exhibit substantial miscalibration (In Hospital Mortality ECE 0.286). We introduce a lightweight, two parameter recalibration method that adapts predictions to local patient populations using 50 to 200 labeled examples, reducing ECE to 0.007. Our findings establish open System One models as a promising zero shot baseline for medical AI, combining competitive predictive performance with low computational cost and efficient local calibration. We release our code and evaluation harness to support future research.

0.24

TrialDesignBench: Benchmarking Language Models for Phase-I Trial Design Against Clinical Knowledge

cs.AI cs.CLstat.AP ·2026-11-09 ·Yihan Hank Tang, Peng Yang, Jiayi Xin, Tianqi Shang, Xuyang Chen +3 more
publishedbenchmarkcode/data similarity 0.69
Abstract · 13 pages, 3 figures, 6 tables. Presented as a poster at the NeurIPS 2026 Workshop on World Models for High-Stakes Health (WMHS). Code and da…

AI is used in much of the clinical trial pipeline. However, selecting the statistical design of a trial, a crucial step that determines how drug doses are tested on humans and evaluated, has seen almost no AI progress. LLMs appear to be a natural fit given their strengths in biomedical knowledge and statistical reasoning. Nevertheless, there is currently no appropriate way to evaluate such abilities because recent regulatory and methodological shifts, most notably FDA's Project Optimus, have redefined what constitutes a reasonable design and rendered many previous designs obsolete. To lay the groundwork for AI-assisted trial design, we introduce TrialDesignBench, a benchmark of 617 Phase-I/I-II oncology dose-finding trials, each paired with an expert-validated reference design that is consistent with the latest FDA regulatory initiatives. This reference standard is produced through a formalization of the expert design process. We evaluate five frontier LLMs, none of which matches the reference standard. Our ablation experiments trace this performance gap to two main causes, inference of latent, unrecorded design determinants from trial sources (supplying them raises class-wise balanced accuracy by 0.22) and structured decision-tree reasoning (+0.24). TrialDesignBench offers a reproducible, contemporary-standard objective for evaluating and enhancing AI-assisted trial design.

0.45

Answering clinicians' questions over trial evidence tables with verifiable, feedback-driven language models

cs.AI ·2026-10-01 ·Manan Roy Choudhury, Suparno Roy Chowdhury, Swastik Sahoo, Muhammad Ali Khan, Kaneez Zahra Rubab Khakwani +3 more
published similarity 0.69
Abstract

Systematic reviews condense clinical trials into evidence tables, yet clinicians can interrogate these tables only through database queries, and many questions concern attributes that the table does not record, such as a drug's target class or a harmonised endpoint. Here we introduce FD-SCoPE, a language-model framework that answers both kinds of question, exposes the query, the selected trials and the derivation rule behind every answer, and learns from expert corrections. On an oncology evidence table of 159 immune checkpoint inhibitor trial records, FD-SCoPE completed all 140 clinician-style tasks (alternatives, 90.7-97.9%). For questions needing derived attributes it retrieved 99.3% of relevant trial records at a positive predictive value of 89.8% and outperformed four alternative approaches (derived-value F1 77.7% versus 64.8-73.4%). Corrections on 299 questions, simulated from reference answers, raised F1 on 1,201 unseen questions from 77.9% to 84.9%. Language models coupled with executable queries, verified programs and expert feedback can give clinicians auditable access to trial evidence.

0.32

Will the Judge Flip? Predicting Position-Sensitive LLM Judgments from Residual Stream Activations

cs.LG cs.AI ·2026-10-05 ·Hashmath Shaik, Gnaneswar Villuri, Alex Doboli
similarity 0.67
Abstract · It was submitted to neurips workshop (JUDGE workshop) and received a review score 6.5 combined with one strong accept and one above threshol…

The order in which candidate responses are presented can change an LLM judge's verdict. Detecting such a position flip ordinarily requires judging each pair in both orders, which doubles the number of judgments. We investigate whether residual stream activations recorded immediately before the initial verdict can predict a flip. We use nested grouped cross-validation to evaluate regularized linear probes on 534 JudgeBench pairs for three Qwen3 judges and Llama-3.1-8B. The linear probes achieve AUROCs of .621-.850 and outperform a combined baseline that uses verbalized confidence, verdict-label logits, response lengths, and the judge's initial choice by .062-.113 AUROC. Linear probes trained on JudgeBench and then frozen achieve AUROCs of .685-.853 on 1,802 MT-Bench comparisons without MT-Bench fitting or recalibration. These results show that pre-verdict activations support prediction of susceptibility to candidate order and outperform the non-activation predictors evaluated here.

0.08

Route, Don't Fix: Regime-Dependent Decoding Correction and a Trajectory-Gated Router for Reliable Clinical LLM Answer Selection

cs.CL cs.AIcs.LG ·2026-09-13 ·Zeyu Dong, Benjamin Wang, Joyee W. Jin
similarity 0.67
Abstract

Large language models (LLMs) are often deemed unsafe for clinical question answering because of their tendency to hallucinate. Retrieval augmentation, fine-tuning, and external verifiers require new infrastructure that clinical governance must approve and may add latency or extra model calls. Inference-time correction uses the model's internal logit signals, but a fixed transformation need not suit every question. A corrector that improves accuracy by about ten percentage points on a truthfulness stress test yields negligible gains on clinical multiple-choice benchmarks, where instruction tuning concentrates output probability on one answer and leaves low terminal entropy. We introduce ALTAS, which reads terminal entropy and late-layer linearity ($R^2$) from one forward pass to choose per question between greedy decoding and late-layer trajectory correction. No classifier, probe, or head is trained; the router operates on candidate-answer logits and adds 6.5% latency overhead. Applied to every question, the correction improves TruthfulQA over greedy at 3B and 8B by 11.4 and 10.0 percentage points, respectively ($p<10^{-10}$). Gated per question, ALTAS retains gains of 8.3 to 9.5 percentage points while keeping MedQA, PubMedQA, and MedHallu within a one-percentage-point do-no-harm band, with no statistically significant differences from greedy. The method passes verification sweeps over frozen thresholds, the scoring rule, and the domain label.

0.21